PH27420A - Pharmaceutically active combination composition comprising as components a as plasminogen activator and as component b herein - Google Patents

Pharmaceutically active combination composition comprising as components a as plasminogen activator and as component b herein

Info

Publication number: PH27420A
Authority: PH; Philippines
Prior art keywords: component; plasminogen activator; components; pharmaceutically active; combination composition
Prior art date: 1988-09-21

Application number

PH39253A

Other languages

English (en)

Inventor

Jutta Heim

Czeslaw Czendlik

Giancarlo Agnelly

Original Assignee

Ciba Geigy Ag

Ucp Gen Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-09-21

Filing date

1989-09-19

Publication date

1993-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10643975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH27420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1989-09-19 Application filed by Ciba Geigy Ag, Ucp Gen Pharma Ag filed Critical Ciba Geigy Ag

1993-06-21 Publication of PH27420A publication Critical patent/PH27420A/en

Links

102000001938 Plasminogen Activators Human genes 0.000 title abstract 2
108010001014 Plasminogen Activators Proteins 0.000 title abstract 2
229940127126 plasminogen activator Drugs 0.000 title abstract 2
208000007536 Thrombosis Diseases 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
102000007625 Hirudins Human genes 0.000 abstract 1
108010007267 Hirudins Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract 1
229940006607 hirudin Drugs 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Wood Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)

PH39253A 1988-09-21 1989-09-19 Pharmaceutically active combination composition comprising as components a as plasminogen activator and as component b herein PH27420A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB888822147A GB8822147D0 (en)	1988-09-21	1988-09-21	Pharmaceutically active combination

Publications (1)

Publication Number	Publication Date
PH27420A true PH27420A (en)	1993-06-21

Family

ID=10643975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH39253A PH27420A (en)	1988-09-21	1989-09-19	Pharmaceutically active combination composition comprising as components a as plasminogen activator and as component b herein

Country Status (15)

Country	Link
US (1)	US5126134A (fr)
EP (1)	EP0365468B1 (fr)
JP (1)	JPH02121934A (fr)
KR (1)	KR0149001B1 (fr)
AT (1)	ATE101524T1 (fr)
AU (1)	AU628854B2 (fr)
CA (1)	CA1336493C (fr)
DE (1)	DE68913132T2 (fr)
DK (1)	DK463989A (fr)
GB (1)	GB8822147D0 (fr)
IE (1)	IE62434B1 (fr)
IL (1)	IL91706A (fr)
NZ (1)	NZ230691A (fr)
PH (1)	PH27420A (fr)
ZA (1)	ZA897173B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8927722D0 (en) *	1989-12-07	1990-02-07	British Bio Technology	Proteins and nucleic acids
US5837808A (en) *	1991-08-20	1998-11-17	Baxter International Inc.	Analogs of hirudin
WO1993014199A1 (fr) *	1992-01-13	1993-07-22	Abbott Laboratories	Procede catalyse par pump-1 de production d'activateur du plasminogene de type urokinase de faible masse moleculaire
ES2149823T3 (es) *	1992-09-03	2000-11-16	Univ California	Factor y composiciones que afectan al tejido dorsal.
CA2124330A1 (fr) *	1992-09-28	1994-04-14	Akiko Sukesada	Nouveau variant de l'hirudine, methode de production et anticoagulant en contenant a titre d'ingredient actif
DE4323754C1 (de) *	1993-07-15	1994-12-01	Gruenenthal Gmbh	Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung
US5972648A (en) *	1993-09-28	1999-10-26	Japan Energy Corporation	Hirudin analogs, methods of manufacture thereof and anticoagulant compositions having these as active ingredients
US5510330A (en) *	1994-03-25	1996-04-23	Boehringer Mannheim Gmbh	Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
US5759542A (en) *	1994-08-05	1998-06-02	New England Deaconess Hospital Corporation	Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
DE4440892A1 (de) *	1994-11-17	1996-05-23	Gruenenthal Gmbh	Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
US7759506B2 (en)	2002-02-25	2010-07-20	Diffusion Pharmaceuticals Llc	Bipolar trans carotenoid salts and their uses
GB2394498B (en) *	2002-10-23	2006-08-09	Engineering Business Ltd	Mounting of offshore structures
GB0306547D0 (en) *	2003-03-21	2003-04-23	Engineering Business Ltd	Apparatus for creating a local reduction in wave height
US20110002978A1 (en)	2003-06-17	2011-01-06	Harrison Roger G	Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
EP1635764A4 (fr) *	2003-06-17	2009-10-21	Roger G Harrison	Conjugue destine au ciblage specifique d'agents anticancereux sur des cellules cancereuses, et production du conjugue
US7976847B2 (en) *	2004-01-13	2011-07-12	Vasogenix Pharmaceuticals, Inc.	Controlled release CGRP delivery composition for cardiovascular and renal indications
JP2007517911A (ja) *	2004-01-13	2007-07-05	バソジェニックスファーマシューティカルズ，インコーポレイテッド	心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
EP1703916A2 (fr) *	2004-01-13	2006-09-27	Vasogenix Pharmaceuticals, Inc.	Procedes pour le traitement d'infarctus myocardique aigu par l'administration du peptide associe au gene de la calcitonine et compositions en contenant
DK1781536T3 (da) *	2004-08-03	2009-03-16	Ihc Engineering Bussiness Ltd	Adgangsmetode mellem marine konstruktioner og apparat
GB0503083D0 (en) *	2005-02-15	2005-03-23	Engineering Business Ltd	Launch and recovery apparatus and method
EP2540696B1 (fr)	2005-02-24	2020-01-01	Diffusion Pharmaceuticals LLC	Transcaroténoïdes, formulation les comprenant et leurs utilisations
GB2428656B (en)	2005-08-01	2009-08-05	Engineering Business Ltd	Gangway apparatus
GB2434823A (en) *	2006-02-06	2007-08-08	Engineering Business Ltd	Transport and installation of offshore structures
CN101687757A (zh)	2007-04-13	2010-03-31	扩散药品有限公司	双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
US20090214469A1 (en) *	2008-02-25	2009-08-27	Jeffrey Gold	Methods and Compositions for the Treatment of Sepsis
EP2445339B1 (fr) *	2009-06-22	2019-08-07	Diffusion Pharmaceuticals LLC	Composé améliorant la diffusion et son utilisation avec un thrombolytique
AU2011262361A1 (en)	2010-06-02	2013-01-10	Diffusion Pharmaceuticals Llc	Oral formulations of bipolar trans carotenoids
US9987241B2 (en)	2014-09-25	2018-06-05	The Board Of Regents Of The University Of Oklahoma	Enzyme conjugate and prodrug cancer therapy
CA3018550A1 (fr)	2016-03-24	2017-09-28	Diffusion Pharmaceuticals Llc	Utilisation de carotenoides trans bipolaires avec une chimiotherapie et une radiotherapie en vue du traitement d'un cancer
US11446365B2 (en)	2017-08-09	2022-09-20	The Board Of Regents Of The University Of Oklahoma	Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
CA3123872A1 (fr)	2018-12-28	2020-07-02	Catalyst Biosciences, Inc.	Polypeptides activateurs de plasminogene de type urokinase modifies et leurs procedes d'utilisation
US11613744B2 (en)	2018-12-28	2023-03-28	Vertex Pharmaceuticals Incorporated	Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8003402A (nl) *	1980-06-11	1982-01-04	Leuven Res & Dev Vzw	Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
DE3342139A1 (de) *	1983-11-22	1985-05-30	Ciba-Geigy Ag, Basel	Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel
JPS61112018A (ja) *	1984-11-06	1986-05-30	Mitsubishi Chem Ind Ltd	線溶増強剤
DE3544318A1 (de) *	1985-12-14	1987-06-19	Behringwerke Ag	Mittel aus einem plasmin-inhibitor und einem plasminogen-aktivator zur behandlung von thrombosen
JP2739050B2 (ja) *	1988-01-28	1998-04-08	ヘキスト薬品工業株式会社	抗血液凝固剤
DE3804600A1 (de) *	1988-02-13	1989-08-24	Basf Ag	Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz

1988
- 1988-09-21 GB GB888822147A patent/GB8822147D0/en active Pending
1989
- 1989-09-12 EP EP89810676A patent/EP0365468B1/fr not_active Revoked
- 1989-09-12 AT AT89810676T patent/ATE101524T1/de not_active IP Right Cessation
- 1989-09-12 DE DE68913132T patent/DE68913132T2/de not_active Revoked
- 1989-09-13 AU AU41352/89A patent/AU628854B2/en not_active Ceased
- 1989-09-18 US US07/408,836 patent/US5126134A/en not_active Expired - Fee Related
- 1989-09-19 CA CA000611903A patent/CA1336493C/fr not_active Expired - Fee Related
- 1989-09-19 NZ NZ230691A patent/NZ230691A/en unknown
- 1989-09-19 PH PH39253A patent/PH27420A/en unknown
- 1989-09-20 DK DK463989A patent/DK463989A/da not_active Application Discontinuation
- 1989-09-20 IL IL91706A patent/IL91706A/xx not_active IP Right Cessation
- 1989-09-20 KR KR1019890013492A patent/KR0149001B1/ko not_active Expired - Fee Related
- 1989-09-20 ZA ZA897173A patent/ZA897173B/xx unknown
- 1989-09-20 JP JP1242356A patent/JPH02121934A/ja active Pending
- 1989-09-20 IE IE301589A patent/IE62434B1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
US5126134A (en)	1992-06-30
DE68913132D1 (de)	1994-03-24
EP0365468A1 (fr)	1990-04-25
IL91706A (en)	1997-07-13
ZA897173B (en)	1990-09-26
AU628854B2 (en)	1992-09-24
KR0149001B1 (ko)	1998-10-15
JPH02121934A (ja)	1990-05-09
DE68913132T2 (de)	1994-07-07
ATE101524T1 (de)	1994-03-15
KR900004349A (ko)	1990-04-12
IE893015L (en)	1990-03-21
IL91706A0 (en)	1990-06-10
AU4135289A (en)	1990-03-29
IE62434B1 (en)	1995-02-08
EP0365468B1 (fr)	1994-02-16
DK463989A (da)	1990-03-22
DK463989D0 (da)	1989-09-20
NZ230691A (en)	1992-03-26
GB8822147D0 (en)	1988-10-26
CA1336493C (fr)	1995-08-01

Publication	Publication Date	Title
PH27420A (en)	1993-06-21	Pharmaceutically active combination composition comprising as components a as plasminogen activator and as component b herein
EP0318201A3 (en)	1990-02-07	Inhibition of arterial thrombotic occlusion or thromboembolism
AU6772387A (en)	1987-06-30	Treatment of thrombosis with fibrinolytic agents and prostacyclines
EP0290998A3 (en)	1990-03-14	Anticoccidial composition
NO178546C (no)	1996-04-17	Analogifremgangsmåte for fremstilling av terapeutisk aktive ACE-hemmere med nootrop virkning
HU9201045D0 (en)	1992-06-29	Combined preparation with antitrombotic effect
AU4090589A (en)	1990-03-08	The use of plasminogen activator inhibitor (pai-2) for immunosuppression
TW284691B (fr)	1996-09-01
EP0618812A4 (fr)	1995-07-19	Utilisation de la protease nexine-i comme anti-inflammatoire.
IL98200A0 (en)	1992-06-21	Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
AU586713B2 (en)	1989-07-20	Pharmaceutical composition having thrombolytic activity
IL98199A0 (en)	1992-06-21	Pharmaceutical compositions containing a derivative of substituted-l-valyl-l-prolinamide
AU612562B2 (en)	1991-07-18	A composition comprising a plasmin inhibitor and a plasminogen activator for the treatment of thrombosis